Novel Suture-Less Vascular Anastomotic Device (BYFix) in Femoro-Popliteal Surgery, Early Clinical Experience
M. Schneider, V. Shapira, V. Chernyavskiy, B. Yoffe
.
DOI: 10.4236/ss.2011.29096   PDF    HTML     4,340 Downloads   7,094 Views   Citations

Abstract

Objectives: To evaluate the early experience of using the BYFix-innovative anastomotic device for creating suture-less vascular anastomosis in major and peripheral arteries surgery. Design: Uncontrolled prospective study. Materials: The BYFix anastomotic device for suture-less vascular anastomosis with surgical tools and standard vascular grafts. Methods: 7 patients, age 63.6 ± 9.2 years, with peripheral vascular occlusion above the knee scheduled for surgical repair were operared. They underwent the surgical procedure using the BYFix anastomotic device for creating proximal anastomosis and the conventional manual suturing for creating the distal anastomosis of the implantable vascular graft. Results: The anastomoses by using BYFix anastomotic device were successfully created in all patients. The duration of anastomosis creation was significantly shorter by using BYFix device, compared to conventional manual suturing, 5:10 ± 1:50 minutes compared to 33 ± 17:40 minutes respectively. No adverse events related to BYFix anastomotic device were observed, during the surgical procedure or recovery period. One year follow up revealed no complications related to BYFix anastomotic device. Conclusions: The BYFix anastomotic device enables the creation of efficient vascular anastomosis in peripheral vascular occlusions. It shortens the time needed for creating vascular anastomosis and thus reducing the operation time and might reduce distal complications related to the vascular procedure. Further clinical trials are needed to establish the results.

Share and Cite:

M. Schneider, V. Shapira, V. Chernyavskiy and B. Yoffe, "Novel Suture-Less Vascular Anastomotic Device (BYFix) in Femoro-Popliteal Surgery, Early Clinical Experience," Surgical Science, Vol. 2 No. 9, 2011, pp. 442-445. doi: 10.4236/ss.2011.29096.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] M. H. Criqui, J. O. Denenberg, R. D. Langer, et al., “The Epidemiology of Peripheral Arterial Disease: Importance of Identifying the Populationat Risk,” Vascular Medicine, Vol. 2, No. 3, 1997, pp. 221-226.
[2] J. M. Murabito, R. B. D’Agostino, H. Silbershatz, et al., “Intermittent Claudication. A Risk Profile from the Framingham Heart Study,” Circulation, 1997, Vol. 96, pp. 44-49.
[3] R. A. Linsky, K. S. Korr and I. Sadiq, “Contemporary Management of Peripheral Arterial Disease: A Review,” Medicine and Health Rhode Island, Vol. 91, No. 10, 2008, pp. 305-308.
[4] A. T. Hirsch, Z. J. Haskal, et al., “ACC/AHA Guidelines for the Management of Patients with Peripheral Arterial Disease (Lower Extremity, Renal Mesenteric, and Abdominal Aortic): Executive Summary: A Collaborative Report from the American Association for Vascular Surgery/Society for Vascular Surgery,” Journal of the American College of Cardiology, Vol. 47, No. 6, 2006, pp. 1239-1312.
[5] M. D. McDaniel and J. L. Cronenwett, “Basic Data Related to the Natural History of Intermittent Claudication,” Annals of Vascular Surgery, Vol. 3, No. 3, 1989, pp. 273-277. doi:10.1016/S0890-5096(07)60040-5
[6] A. M. Imparato, G. E. Kim, T. Davidson and J. G. Crowley, “Intermittent Claudication: Its Natural Course,” Surgery, Vol. 78, No. 6, 1975, pp. 795-799.
[7] N. N. Dagher and J. G. Modrall, “Pharmacotherapy before and after Revascularization: Anticoagulation, Antiplatelet Agents, and Statins,” Seminars in Vascular Surgery, Vol. 20, No. 1, 2007, pp. 10-14.
[8] B. Yoffe, et al., “Experimental Study of a Novel Suture-Less Aortic Anastomotic Device,” European Journal of Vascular and Endovascular Surgery, Vol. 34, No. 1, 2007, pp. 79-86. doi:10.1016/j.ejvs.2007.02.004

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.